New Trial for Individuals with Adenocarcinoma of the Lung

22 Apr

Proud to have access to the latest research, The Oncology Institute of Hope and Innovation has technology and treatment options, including clinical trials for eligible patients. We are dedicated to providing comprehensive medical services to our patients. We participate in numerous clinical trials focused on various types of malignancies that may be of interest to your oncology patients in our quest to be at the forefront of the latest medical cancer research.  We are pleased to announce the opening of the following clinical trial for individuals with adenocarcinoma of the lung which may benefit some of your patients:

 

A Multicenter, Open-Label Phase 2 Study of the

Safety and Activity of Lenvatinib (E7080) in Subjects With

KIF5B-RET-Positive Adenocarcinoma of the Lung. 

The primary objective is to evaluate the objective response rate (ORR) in subjects treated with lenvatinib in KIF5B-RET-positive adenocarcinoma of the lung.

If you have patients who you feel may qualify for this trial, or have questions regarding eligibility, please contact any one of our offices to schedule an evaluation.  We look forward to working with you.

Latest Clinical Trial Open to Patients with Pancreatic Cancer

22 Apr

The Oncology Institute of Hope and Innovation is proud to have access to the latest research, technology and treatment options, including clinical trials for eligible patients. We are dedicated to providing comprehensive medical services to our patients.  In our quest to be at the forefront of the latest medical cancer research, we participate in numerous clinical trials focused on various types of malignancies that may be of interest to your oncology patients.  We are pleased to announce the opening of the following clinical trial for individuals with advanced pancreatic cancer which may benefit some of your patients:

 

A Randomized, Safety and Exploratory Efficacy

Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus

Gemcitabine in Patients with Advanced Pancreatic Cancer

 

The primary objective of this Phase IIb protocol is to evaluate in a preliminary manner the efficacy of Kanglaite Injection plus gemcitabine relative to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer, not amenable to curative surgical resection, as measured by Progression-Free Survival (PFS).

If you have patients who you feel may qualify for this trial, or have questions regarding eligibility, please contact any one of our offices to schedule an evaluation.  We look forward to working with you.

 

Casino Night Fundraiser

5 Apr

Casino Night Flyer 2013

 

The Foundation of Hope and Innovation is having our 3rd annual Casino Night Fundraiser for cancer research.

Join us for a fun-filled night of casino games, raffle prizes, and a display of photographs submitted by our patients for the “My Happy Moment” photography contest.

$10 entry gets you some chips to play with. RSVPing on our Facebook page gets you $5 off of your entrance fee!

Come have a great time time, raise money for charity, and have a chance to win fantastic prizes such as an iPad, iPods, or even a TV!

All proceeds will go to The Foundation of Hope and Innovation to aid the fight against cancer through research and education.

Complimentary food and beverages will be served.

If you cannot attend, but would like to make a contribution to the cause, please send us a message with your email address and we will contact you.

We thank you for your support.

We hope to see you there!

New Clinical Trial Available for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

1 Apr

The Oncology Institute of Hope and Innovation is proud to have access to the latest research, technology and treatment options, including clinical trials for eligible patients. We are dedicated to providing comprehensive medical services to our patients.  In our quest to be at the forefront of the latest medical cancer research, we participate in numerous clinical trials focused on various types of malignancies that may be of interest to your oncology patients.  We are pleased to announce the opening of the following clinical trial for individuals with non-small cell lung cancer which may benefit some of your patients:

An Open-Label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After First-Line Treatment with Bevacizumab Plus A Platinum Doublet-containing Chemotherapy (MO22097)

The primary objective is to assess the efficacy of continuous bevacizumab treatment beyond 1st progression of disease (PD1) as measured by overall survival (OS). The secondary objective is to assess the efficacy as measured by rate of 6-, 12-, and 18-month OS as measured from randomization at PD1.

If you have patients who you feel may qualify for this trial, or have questions regarding eligibility, please contact any one of our offices listed below to schedule an evaluation.  We look forward to working with you.

Patient Spotlight: John L. Ivins

4 Mar

John-IvinsJohn L. Ivins was just going to get a cough checked out when he made his doctor’s appointment last April. After a bout with pneumonia and a bone marrow biopsy, he was diagnosed with Acute Myeloid Leukemia.  The news hit him and his family like a ton of bricks and they turned to their supportive friends and faith for strength.

From Long Beach, John is married to his wife, Maureen, and together, they have four children and nine grandchildren.  He works for a company that manufactures sewage and industrial waste handling pumps and electrical control systems and in his free time, he enjoys going camping with his family in their motor home and coaches water polo for his grandson’s team. John has also been a surfer for 47 years.

Treated by Dr. Eric Cheung, John went through five months of treatment which involved a long hospital stay followed by a five-day hospital stay every thirty days for four rounds of consolidation therapy.  Throughout this difficult time, John had the support and love of his family and friends. He was never alone when he was in the hospital getting his treatments.

Officially in “remission” as of January 29th, 2013, John and his family are very grateful and happy with the care they received from Dr. Cheung and the staff at The Oncology Institute.  As he transitions back into the work force, John looks forward to getting back into the water to coach again.

Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial.

14 Feb
Sub-category:

Prostate Cancer

Category:

Genitourinary Cancer

Meeting:

2012 ASCO Annual Meeting

Session Type and Session Title:

Poster Discussion Session, Genitourinary (Prostate) Cancer

Abstract No:

4550

Citation:

J Clin Oncol 30, 2012 (suppl; abstr 4550)

Author(s):

Andrew J. Armstrong, Michael Haggman, Walter Michael Stadler, Jeffrey R. Gingrich, Vasily J. Assikis, Jonathan Polikoff, Samuel R. Denmeade, Daniel J. George, Cal Andreou, William R. Clark, Paul Sieber, Richy Agajanian, Laurence Belkoff, Jan-Erik Damber, Orjan Nordle, Goran Forsberg, Michael Anthony Carducci, Roberto Pili; Duke Cancer Institute, Durham, NC; University of Uppsala, Uppsala, Sweden; The University of Chicago, Chicago, IL; University of Pittsburgh, Pittsburgh, PA; Peachtree Hematology Oncology Consultants, Atlanta, GA; National Surgical Breast and Bowel Project and Kaiser Permanente Southern California, San Diego, CA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Andreou Research, Surrey, BC, Canada; Alaska Clinical Research Center, Anchorage, AK; Urological Associates of Lancaster, Ltd., Lancaster, PA; Agajanian Inst of Onc and Hem, Whittier, CA; Urologic Consultants of SE PA, Bala Cynwyd, PA; Urologmottagningen, Goteborg, Sweden; Active Biotech, Lund, Sweden; The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY

Abstracts that were granted an exception in accordance with ASCO’s Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures

Abstract:

Background: Tasquinimod (T) is an oral quinoline-3-carboxamide derivative that binds S100A9 protein and has preclinical anti-angiogenic and anti-tumor activity. Between 12/07-6/09, 201 (134 T, 67 Placebo (P)) men with metastatic CRPC were randomized and received treatment once-daily at an initial dose of 0.25 mg/day escalated to 1.0 mg/day over 4 weeks. Placebo patients could cross over to T after 6 months or at disease progression. The primary endpoint of improved PCWG2 criteria-defined progression at 6 months was met (69 vs. 37% of patients (T/P) were progression free) with PFS of 7.6 vs. 3.3 months for pts on T vs. P1 with acceptable toxicity. This abstract provides the first analysis on symptomatic progression, overall survival (OS) as well as a multivariate analysis for PFS and OS. Methods: Survival data were collected between June 2011 and January 2012 with a median time to censoring of 32 months. Survival data was also evaluated in an exploratory multivariate model of known prognostic factors in CRPC. Results: An imbalance of several baseline prognostic criteria favored placebo (e.g. baseline PSA of 29 vs. 19 (T/P)) (JCO 2011;20:4022). Time to symptomatic progression was longer in T treated patients (p=0.039, HR=0.42). Record of death (97 events) or survival >13 months was documented in 182 patients. Median time to death was 34.2 vs. 30.2 months (T/P). Median time to death in the PCWG2 bone-metastatic subgroup (N=92/44) was 34.2 vs. 25.6 months. A multivariate analysis of known prognostic factors including PSA, LDH, PSA kinetics, and hemoglobin demonstrated an adjusted HR for PFS of 0.54 (95% CI 0.37,0.81) and OS of 0.72 (95% CI 0.46,1.12) in the total population and 0.63 (95% CI 0.37,1.07, n=136) in the bone-metastatic group. Conclusions: OS observed after tasquinimod treatment is longer than previously reported in this patient population. The current exploratory data indicates that the prolongation in PFS observed with tasquinimod treatment may lead to a survival advantage in men with metastatic CRPC. A phase III placebo-controlled study (NCT01234311) is ongoing in men with bone-metastatic CRPC powered to detect an OS improvement.

A clinical trial of the treatment of patients with epithelial ovarian cancer (EOC) using autologous dendritic cell therapy targeting mucin-1.

5 Feb

Abstract #115521

A clinical trial of the treatment of patients with epithelial ovarian cancer (EOC) using autologous dendritic cell therapy targeting mucin-1.
James Fiorica, Jeffrey C. Goh, Nana Eleonore Tchabo, Fernando O Recio, Richy Agajanian, Richard D. Drake, Jeremy Power, Saul E. Rivkin, Sumitra Ananda, Sharron Gargosky; Sarasota Memorial Hospital, Sarasota, FL; Royal Brisbane and Women’s Hospital, Brisbane, Australia; Atlantic Health Carol G. Simon Cancer Center, Morristown, NJ; Florida Center for Gynecologic Oncology, Boca Raton, FL; Agajanian Inst of Onc and Hem, Whittier, CA; Cleveland Clinic, Cleveland, OH; Launceston General Hospital, Launceston, Australia; Swedish Cancer Inst, Seattle, WA; Royal Melbourne Hospital, Victoria, Australia; PrimaBioMed, Sydney, Australia

Abstract Text:

Background:  Cvac™ (Cvac) is an autologous dendritic cell immunotherapy that targets mucin-1 positive tumors.  The enrolling study, CANVAS (CANcer VAccine Study) is evaluating Cvac treatment of EOC patients in first remission after surgery and standard chemotherapy, with at least three cycles of platinum and taxane therapy. The primary endpoint is progression free survival, and the secondary endpoints include overall survival, safety evaluation and quality of life scores Methods:  Patients are eligible if they have stage III or IV mucin-1 positive EOC and have had optimal cytoreductive (<1cm residual disease) surgery. Cell collection occurs prior to the start of chemotherapy. Patients remain eligible for the study if they have a complete remission based on radiological, clinical and biochemical outcomes. Treatment of intradermal injections is every four weeks for three doses, and every twelve weeks for three additional doses. Disease progression is determined by radiological results at the clinical center but is also centrally read by blinded evaluators.   To date there is approval in Australia, Belgium, Bulgaria, Belarus, Germany, Lithuania, Poland, Ukraine, USA. Submissions are underway in France, Romania, Latvia, Austria, Korea and Thailand. It is expected that over 100 centers will participate. As of data review, there were 14 active sites with the initial 26 patients screened, 23 randomized with an average age of 57 +/- 10 years with multiple patients achieving complete remission and starting treatment. The first dosed patient was in Australia on January 24 2013. No treatment-emergent events were reported.

Thomas F. Reynolds, M.D., FACP joins The Oncology Institute of Hope and Innovation team of specialists

31 Jan

TFR photo smallA firm believer in providing quality care to both patients and their families, Dr. Reynolds is triple-board certified by the American Board of Internal Medicine, American Board of Medical Oncology, and American Board of Hospice and Palliative Medicine. Fellowship trained in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, Dr. Reynolds earned his medical degree at Ohio State University College of Medicine in 1974 and completed his residency over at Carney Hospital at Boston University.  Dr. Reynolds also has two graduate degrees, which include a M.S. in Physical Chemistry from Northwestern University and a M.B.A. from Rensselaer Polytechnic Institute.

Besides his vast experience as a medical oncologist, Dr. Reynolds has also held several academic appointments, including serving as an Assistant Professor of Medicine over at Albany Medical College and Boston University’s School of Medicine.  He also served as the Instructor of Medicine at Cornell University’s Medical College.

As the first board certified physician with the American Board of Hospice and Palliative Medicine to join the team of oncologists and hematologists at The Oncology Institute of Hope and Innovation, Dr. Reynolds will be seeing patients out of their Montebello location and will be expanding the group’s presence in more local hospitals around the San Gabriel Valley.

Dr. Reynolds believes that the best care address the medical, social, psychological, and spiritual issues that arise while providing restorative, curative, or life-prolonging treatment. “This is the core of what palliative care provides patients. It also includes awareness of all ethical modes of care such as acupuncture, massage, chiropractic, nutritional supplements, and prayers are just some of the many.”

Dr. Reynolds will be joining twelve other physicians on staff at The Oncology Institute of Hope and Innovation starting February 4th, 2013.

Patient Spotlight: June Brown

2 Jan

June Brown

Diagnosed with Stage II Breast Cancer in November of 2008, 48-year old June Brown had a lumpectomy, eight sessions of aggressive chemotherapy, seven weeks of radiation and is currently still taking hormone blockers. Treated by Dr. Richy Agajanian, June has been cancer free now for the last three years.

Born in Los Angeles, June currently resides in Downey with her husband, Terrance Brown.  They have two wonderful children, Candice and Terrance Junior, and two grandchildren, Terrance and Greg.  June works as an Administrative Assistant with Columbia Management.  In her spare time, she loves to sing Gospel, R&B, and different genres of music and volunteers her singing talents from time to time at various events.

Throughout her treatments, June found her strength through her faith and her family.  It was a difficult time for her, but she never gave up. There were times she felt like giving up because of the side effects during chemo and negative thoughts. “I attend church on a regular basis and it is a lifestyle for me. I could not live successfully without it. I am more relaxed and I finally have peace of mind… more than I ever had in my entire life.”   (continued on back page)
June also is proud of her marriage and her family. “I am married to someone who loves and supports me. He is one of the most awesome men in the world. We are a close family and we enjoy one another.”

When she had the strength during her treatments, June did things she would normally do, such as walking in the park and going to events. She even took up cooking because she started watching the cooking channel a lot. Now that June is cancer free, she continues to improve her cooking along with just doing things she enjoys. “I am encouraged today and very excited about where I came from and where I am today!”

Healthy Resolutions for the New Year

28 Dec

sports_girl_healthy_food

Most people typically make a health-related New Year’s resolution each year.  And while resolutions like losing weight, exercise more, and quitting bad habits such as smoking are all great resolutions to have, it may be easier to keep those resolutions if you scale down your own expectations and set more manageable goals.  Consider these:

Control Your Portions by Using Smaller Plates

Want to downsize your figure? Start downsizing your dishes. Studies show using smaller plates and bowls promote weight loss because they help to curb overeating.

10-Minute Strength Training Sessions

In simply 10 minutes a day you could gain more energy, stronger bones, and a faster metabolism — and you don’t even need to lift dumbbells. Do exercises such as squats, push-ups, lunges, and abdominal exercises. Adding these moves to your exercise program will help you burn more calories in less time.

Cut back on alcohol

While much has been written about the health benefits of a small amount of alcohol, too much tippling is still the bigger problem. (In fact, binge drinking seems to be on the rise.)

Drinking alcohol in excess affects the brain’s neurotransmitters and can increase the risk of depression, memory loss, or even seizures.

Chronic heavy drinking boosts your risk of liver and heart disease, hypertension, stroke, and mental deterioration, and even cancers of the mouth, throat, liver, and breast.

Get Serious About Breathing Exercises

Simple breathing techniques offer a drug-free way to help lower your blood pressure, calm a racing heart, or settle an upset digestive system. Proper breathing has direct influence on emotional states and moods. When you’re upset, you breathe rapidly, shallowly, and irregularly, but you can’t be upset if your breathing is slow, deep, quiet and regular. At first, the effects are subtle, but they will gain power the more you repeat them. Whether you want to address health problems or just relax and reduce stress, make this the year to learn and practice some proper breathing techniques.

Take Time for Tea

Drinking green tea can improve your cholesterol ratio, as well as help protect against cancer and bacterial infections. The difference between green and the more familiar black tea is in the preparation: both come from the same plant, Camellia sinesis, but to make black tea, leaves go through an oxidation process that darkens them. This process deceases some of tea’s beneficial compounds, including polyphenols called catechins. Green tea is unfermented, which means that it contains more catechins. But don’t think of tea drinking only as a utilitarian way to imbibe those healthful compounds. Learn to appreciate the subtle fragrance of good quality green tea and use tea time to unwind, meditate and as a respite from your stress du jour. Here are nine green teas to consider.

Slash Sodium Consumption

Studies show many Americans consume close to twice the recommended limit of sodium, which is a teaspoon (or 6 grams) daily. Besides contributing to water retention (think bloat!), sodium can raise blood pressure. Processed foods contain the most, so make sure to read labels. Lower sodium diets are linked to decreased risk of heart disease, but are also associated with lower hypertension and weight management.

Floss Your Teeth

Like many people, you may not know that bacteria in your mouth can lead to serious problems if you neglect oral health. You may also be surprised to learn that during routine exams, your dentist can spot indications of diabetes and heart disease. One simple thing you can do to head off bacteria is floss your teeth.

Wear Sunscreen… All Year

Sun exposure affects everyone. According to the National Cancer Institute most skin cancer develops after age 50, though sun damage starts at an early age. The sun’s rays are also behind brown spots, and can make wrinkles appear before their time. Wear a broad spectrum sunscreen, even in the winter, anywhere skin is laid bare to the elements.

Cut your stress

A little pressure now and again won’t kill us; in fact, short bouts of stress give us an energy boost. But if stress is chronic, it can increase your risk of—or worsen—insomnia, depression, obesity, heart disease, and more.

Long work hours, little sleep, no exercise, poor diet, and not spending time with family and friends can contribute to stress, says Roberta Lee, MD, an integrative medicine specialist at Beth Israel Medical Center, in New York City, and the author of The Super Stress Solution.

“Stress is an inevitable part of life,” she says. “Relaxation, sleep, socializing, and taking vacations are all things we tell ourselves we deserve but don’t allow ourselves to have.”

Volunteer

We tend to think our own bliss relies on bettering ourselves, but our happiness also increases when we help others, says Peter Kanaris, PhD, coordinator of public education for the New York State Psychological Association.

And guess what? Happiness is good for your health. A 2010 study found that people with positive emotions were about 20% less likely than their gloomier peers to have a heart attack or develop heart disease. Other research suggests that positive emotions can make people more resilient and resourceful.

Service organizations always appreciate donated money, but giving of yourself, especially in a way that draws on your unique talents or skills, is more satisfying. You can volunteer to feed the homeless, help people with terminal illnesses, and help to clean up the environment. Donate clothing you no longer wear and other items you don’t use. Look for ways to help those close to home: take meals to shut-ins, offer transportation to elderly or disabled neighbors and tutor or read to children. Don’t focus only on the needs of strangers. Look for ways to help friends and family members, too.

Travel

The joys and rewards of vacations can last long after the suitcase is put away. “We can often get stuck in a rut, and we can’t get out of our own way,” Kanaris says. “Everything becomes familiar and too routine.”

But traveling allows us to tap into life as an adventure, and we can make changes in our lives without having to do anything too bold or dramatic.

“It makes you feel rejuvenated and replenished,” he adds. “It gets you out of your typical scenery, and the effects are revitalizing. It’s another form of new discovery and learning, and great for the body and the soul.”

Follow

Get every new post delivered to your Inbox.

Join 2,432 other followers

%d bloggers like this: